Paradigm Reports Phase 3 Trial Futility as Administrators Review Next Steps
PAR: $0.245 +0.00% · MC: $153M
Paradigm Biopharmaceuticals reported that its Phase 3 trial met the pre-set futility criterion, and voluntary administrators were appointed at quarter-end. Since then, a regional analysis identified encouraging pain and function findings, while independent review of the data is underway to inform assessment of the program and possible future development. The company ended the quarter with approximately A$4 million in cash; a recent court-approved extension gives administrators until January to convene a creditors’ meeting, though they anticipate acting sooner.

Comments